Cic edizioni internazionali
Functional Neurology

Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal

Review, 7 - 18
doi: 10.11138/FNeur/2018.33.1.007
Tag this article
Abstract
Enhanced HTML Full text PDF
Three different type A botulinum neurotoxins (BoNTAs) — onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA) — are currently marketed in Europe to treat several conditions. Differences between BoNTA preparations, which depend on their
specific biotypes and manufacturing processes, lead to clinically relevant pharmacotherapeutic dissimilarities.
All three available products are separately recognized and reviewed in American Academy of Neurology guidelines. The neurotoxin load/100U is likewise different among the different BoNTAs, with the result that the specific potency of the 150kD BoNTA neurotoxin is calculated as 137 units/ng for onabotulinumtoxinA, 154 units/ng for abobotulinumtoxinA, and 227 units/ng for incobotulinumtoxinA. It is important for clinicians to have all three BoNTAs available in order to choose the most suitable preparation for the specific indication in the single patient. Commercially available BoNTAs must be recognized as different from one another, and therefore as non-interchangeable.
The essential experience of the clinician is of the utmost importance in choosing the most appropriate treatment.

Vol. XXXIII (No. 2) 2018 April/June

  1. Shorter acute care hospital stay, longer stay in post-acute care facilities
    Formisano R., Contrada M., Aloisi M.
    doi: 10.11138/FNeur/2018.33.2.065
  2. Understanding the pathophysiology of hyperglycemia-associated chorea-ballism: a systematic review of positron emission tomography findings
    Gómez Ochoa S. A., Espín Chico B.B.
    doi: 10.11138/FNeur/2018.33.2.067
  3. A review of 500 patients with acute stroke admitted to the University Hospital of Saudi Arabia. Similarities and differences compared with the published literature
    Zafar A.
    doi: 10.11138/FNeur/2018.33.2.073
  4. Direction-specific cortical response immediately after moving tactile stimuli in female humans
    Hiraoka K., Kento Y., Kiya H., Nozaki Y., Hayashi T.
    doi: 10.11138/FNeur/2018.33.2.081
  5. Impact of epilepsy after severe brain injury on safe resumption of driving: two-year follow-up
    Saviola D., De Tanti A., Delsoldato S., Chiari M., Inzaghi M.G., Baldari F.
    doi: 10.11138/FNeur/2018.33.2.091
  6. Epidemiological and clinical characteristics of 492 patients in a vegetative state in 29 Italian rehabilitation units. What about outcome?
    Avesani R., Dambruoso F., Scandola M., Formisano R., De Tanti A., Ferro S., Smania N., Roncari L., Rossato E.
    doi: 10.11138/FNeur/2018.33.2.097
  7. Laterality in Parkinson’s disease may predict motor and visual imagery abilities
    Lo Monaco M.R., Laudisio A., Fusco D., Vetrano D.L., Ricciardi D., Delle Donne V., Proietti F., Zuccalà G., Silveri M.C.
    doi: 10.11138/FNeur/2018.33.2.105
  8. Development of a patient-centered questionnaire for post-stroke spasticity assessment: a reliability study
    Baricich A., Cosenza L., Sandrini G., Paolucci S., Morone G., Santamato A., Cinone N., Peri E., Picelli A., Invernizzi M., Ferriero G.
    doi: 10.11138/FNeur/2018.33.2.113
  9. Musculoskeletal impairment and functional limitations in a patient affected by mutation in the laminin a-5 gene
    Liguori S., de Sire A., Moretti A., Sodano L., Sampaolo S., Gimigliano F., Iolascon G.
    doi: 10.11138/FNeur/2018.33.2.117
Last Viewed articles: la lista degli ultimi x visitati.
  1. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal
    Ferrari A., Manca M., Tugnoli V., Alberto L.
    doi: 10.11138/FNeur/2018.33.1.007
credits